Enlivex Therapeutics Shares Scheduled to Reverse Split on Tuesday, October 27th (NASDAQ:ENLV)

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s stock is set to reverse split on Tuesday, October 27th. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, October 26th.

Enlivex Therapeutics Price Performance

Shares of NASDAQ:ENLV traded down $0.03 during midday trading on Friday, reaching $0.17. The company’s stock had a trading volume of 655,132 shares, compared to its average volume of 2,489,173. Enlivex Therapeutics has a 1 year low of $0.17 and a 1 year high of $27.15. The business has a 50 day moving average price of $0.79 and a 200 day moving average price of $6.06.

Analyst Ratings Changes

ENLV has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Tuesday, September 22nd. Finally, Zacks Research lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $247.50.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd purchased a new stake in shares of Enlivex Therapeutics during the 2nd quarter valued at about $55,000. Bank of America Corp DE lifted its position in Enlivex Therapeutics by 53.2% during the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after acquiring an additional 45,303 shares in the last quarter. Finally, Susquehanna International Group LLP lifted its position in Enlivex Therapeutics by 1,428.5% during the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after acquiring an additional 147,334 shares in the last quarter. 1.02% of the stock is owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company developing immunotherapies designed to restore immune-system balance in conditions associated with excessive or dysregulated inflammation. The company is based in Israel and trades on the Nasdaq under the symbol ENLV.

Enlivex’s lead product candidate is Allocetra, an investigational, off-the-shelf cell therapy intended to reprogram immune cells known as macrophages and promote immune homeostasis. The therapy is being studied as a potential treatment for severe inflammatory conditions, including sepsis and osteoarthritis of the knee.

The company’s clinical development activities have included studies in Israel and other locations, with programs focused on evaluating Allocetra’s safety and potential efficacy.